[M20-178] Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus Best Available Therapy

Authors
Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2021
This article has no abstract
Epistemonikos ID: d09c6c85aeace364d3ca347c7191b539babe258c
First added on: Apr 11, 2025